Slide 1: Investor Presentation
Investor Presentation August 10, 2026 NASDAQ: TCMD
Slide 2: Forward-Looking Statements & Non-GAAP Financial Information
Forward-Looking Statements & Non-GAAP Financial Information Forward Looking Statements This presentation contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,
Slide 3: Revealing & Treating Patients with Underserved Chronic Conditions
Revealing & Treating Patients with Underserved Chronic Conditions… …including: Chronic Swelling/ Lymphatic Dysfunction Inflammatory Lung Disease TACTILE MEDICAL | 3
Slide 4: Leadership Team
Leadership Team Decades of Combined Experience and Leadership in the Medical Device Industry Sheri Dodd Elaine Birkemeyer Nicolaus Wilson Kristie Burns Aaron Snodgrass Jerry Sauber James Berg Chief Executive Officer Chief Financial Officer SVP, Marketing & SVP, Business SVP, Sales SVP, Manufacturing
Slide 5: Underpenetrated, $10B Large TAM
Underpenetrated, $10B ~2.5M ~25M Large TAM Total Addressable Market1 Diagnosed Populations2 Undiagnosed Populations3 Scaled, Market >95,000 $330M Leading Position Patients Served in 2025 2025 Total Revenue Demonstrated 76% $45M $43M Profitability 2025 Gross Margin 2025 Adj. EBITDA4 2025 Operating Ca
Slide 6: Chronic & Progressive, Underdiagnosed & Undertreated Disease States
Chronic & Progressive, Underdiagnosed & Undertreated Disease States Significant Gaps in Both Diagnosis and 2M 1 Access to Effective Treatment 500K 4 D I AG N OS E D D I AG N OS E D LY MPH EDEMA I N T H E B RONCH IECTAS IS I N U. S . T H E U. S . 20M+ U ND I AG N OS E D 2,3 4.4M 5,6 I N T H E U. S. U
Slide 7: Significant Opportunity to Improve Access to Critically Underserved Patient Populations
Significant Opportunity to Improve Access to Critically Underserved Patient Populations LY MPH EDEMA B RONCH IECTAS IS $5B+ CU R R E N T A D DR ESSA B LE $5B+ CU R R E N T A D DR ESSA B LE $10B+ TOTAL ADDRESSABLE M A R KE T M A R KE T MARKET* Gaps in Patient Education and Access Present an Opportuni
Slide 8: Significant Opportunity to Improve Access to Critically Underserved Patient Populations
Significant Opportunity to Improve Access to Critically Underserved Patient Populations LY MPH EDEMA B RONCH IECTAS IS $5B+ CU R R E N T A D DR ESSA B LE $5B+ CU R R E N T A D DR ESSA B LE $10B+ TOTAL ADDRESSABLE M A R KE T M A R KE T MARKET* Gaps in Patient Education and Access Present an Opportuni
Slide 9: Lymphedema Has Many Causes and Affects People of all Backgrounds
Lymphedema Has Many Causes and Affects People of all Backgrounds What is It? How Does it Occur? The lymphatic system enables the transport of fluids containing ▪ Chronic venous ▪ Trauma infection-fighting white blood cells. insufficiency (CVI) ▪ Surgery When the lymphatic system is damaged or impair
Slide 10: Less Than 10% of Diagnosed Patients Receive a Solution to Treat Their Symptoms
As a Result, Less Than 10% of Diagnosed Patients Receive a Solution to Treat Their Symptoms Lymphedema Symptoms Include: ▪ Cellulitis ▪ Skin changes ▪ Swelling ▪ Pain & tightness ▪ Hard-to-heal wounds ▪ Dysphagia ▪ Limb heaviness ▪ Inability to swallow ▪ Fibrosis ▪ Limited range of motion Most patie
Slide 11: The Care Journey is Long and Complex, with Countless Friction Points
The Care Journey is Long and Complex, with Countless Friction Points Undiagnosed Diagnosis Treatment Pre-Awareness Awareness Conservative Therapy ICP* Order Process Home-Based Therapy Limited disease education Conservative therapy delays care Administrative barriers Variable patient experience • 60%
Slide 12: Tactile Medical Delivers Differentiated Solutions: Product and Service
Tactile Medical Delivers Differentiated Solutions: Product and Service Legacy Systems Recent & Upcoming Innovation Basic Device: ENTR E PLUS® Basic Device: NIMB L® Convenient, at-home Smaller, lighter, and portable treatment for lymphedema solution for use at home or on and chronic swelling designed
Slide 13: Proven Clinical Efficacy Drives Consistent and Effective Therapy
Proven Clinical Efficacy Drives Consistent and Effective Therapy 88% 85% 96% 37% experienced lower improved ability to satisfaction with reduction in total limb volume perform activities of Flexitouch lymphedema-related reduction with daily living1 treatment2 costs per patient3 Flexitouch1 Existing
Slide 14: Flexitouch Plus Further Validated in Treating Head & Neck Cancer-Related Lymphedema
Flexitouch Plus Further Validated in Treating Head & Neck Cancer-Related Lymphedema Data Overview • Six-month results from Tactile Medical’s clinical trial examining the effectiveness of Flexitouch Plus vs. usual care in treating lymphedema among head and neck cancer survivors • Data shows sustained
Slide 15: Kylee App Enables Personalized Treatment and Patient Engagement
Kylee App Enables Personalized Treatment and Patient Engagement Learn Personalized information to help patients understand their condition Track Symptom & treatment tracking to understand how therapy is progressing Share Converts treatment data into reports that can be shared with care team TACTILE
Slide 16: LymphaTech Acquisition Adds Portfolio Breadth & Depth
LymphaTech Acquisition Adds Portfolio Breadth & Depth, Advancing Evolution to Integrated Solutions Leader About LymphaTech’s Technology Immediate Strategic Value for Tactile Long-Term Vision for Tactile • FDA-cleared digital platform for fluid • Improves disease identification via • Now – SaaS-based
Slide 17: Removing Friction Points Across the Care Continuum
Removing Friction Points Across the Care Continuum: Strategic Investment Supported by Structural Tailwinds Undiagnosed Diagnosis Treatment Pre-Awareness Awareness Conservative Therapy ICP* Order Process Home-Based Therapy Limited disease education Conservative therapy delays care Administrative barr
Slide 18: Market Leadership and Robust Sales Force Strengthened By Distinct Barriers to Entry
Market Leadership and Robust Sales Force Further Strengthened By Distinct Barriers to Entry • Integrated direct-to-patient/provider model Vertically Integrated Model • In-house DME operations with oversight of entire order process: manufacturing, claims processing, collections, and RCM • Efficient
Slide 19: Lymphedema Market Fundamentals & Strategy
Lymphedema Market Fundamentals & Strategy ~145K 1 Number of diagnosed patients treated annually Diagnosed patients treated with a PCD or NPCD with PCD/NPCD is growing ~10%1 2M1 Addressable diagnosed U.S. patients Significant annual addressable market without PCD or NPCD treatment Near-term commercia
Slide 20: Owning the Space with Lymphedema Solutions that Improve Patient's Lives
Owning the Space with Lymphedema Solutions that Improve Patient’s Lives #1* ▪ CLI N I CA LLY PR OV EN P N EU M ATI C CO M PR ESSI O N D EV I CES M A R KE T S H AR E ▪ EX PA N D IN G CLI N IC A L EV ID EN CE ▪ LA R G E SA LES R EA CH $5B+* TOTAL AD D RES S AB L E ▪ ▪ SC A LA B LE BA C K O FF I CE C A
Slide 21: Significant Opportunity to Improve Access to Critically Underserved Patient Populations
Significant Opportunity to Improve Access to Critically Underserved Patient Populations LY MPH EDEMA B RONCH IECTAS IS $5B+ CU R R E N T A D DR ESSA B LE $5B+ CU R R E N T A D DR ESSA B LE $10B+ TOTAL ADDRESSABLE M A R KE T M A R KE T MARKET* Gaps in Patient Education and Access Present an Opportuni
Slide 22: Bronchiectasis is Among the Most Common Respiratory Diseases
Bronchiectasis is Among the Most Common Respiratory Diseases What is It? Bronchiectasis is a complex respiratory disease that causes airways to be abnormally widened, inflamed, and scarred, leading to permanent damage. Damaged airways can no longer clear mucus and bacteria from airways and lungs, ca
Slide 23: Too Many Bronchiectasis Patients are Not Receiving Access to Quality-of-Life Restoring Treatment
Too Many Bronchiectasis Patients are Not Receiving Access to Quality-of-Life Restoring Treatment Routinely left untreated If treated, first-line options not effective for many patients L E F T U N T R E AT E D BA S IC APPR OAC H S TA N D A R D O F C A R E ▪ Antibiotics for ▪ Chest physiotherapy ▪ Co
Slide 24: Tactile is Advancing the Bronchiectasis Treatment Paradigm with Proven At-Home Therapy
Tactile is Advancing the Bronchiectasis Treatment Paradigm with Proven At-Home Therapy NEXT-GENERATION AFFLOVEST® Next-generation AffloVest launched June 2026 ▪ High frequency chest wall oscillation (HFCWO) therapy ▪ Lighter, more adjustable vest and redesigned controller improve comfort and ease of
Slide 25: Leading the Market with Patient-Friendly Airway Clearance Therapy
Leading the Market with Patient-Friendly Airway Clearance Therapy #1* ▪ DIFFERENTIATED PORTABLE DESIGN M A R KE T S H AR E ▪ BROAD DME CHANNEL REACH $5B+ * TOTAL AD D RES S AB L E ▪ AFFLOVEST FITS COMPLEX RESPIRATORY PATIENT ALREADY ON-SERVICE MA RKE T ▪ STRONG REIMBURSEMENT *Based on management est
Slide 26: Well-Defined Go-to-Market Strategy
Well-Defined Go-to-Market Strategy Lymphedema: Direct Sales Force Bronchiectasis: Indirect Sales Force Selling Through Established Call Points Selling Through DME1 Partners ~275M Vascular Practices Oncology Practices Respiratory DMEs Covered Lives Lymphatic Therapists Veterans Affairs Account Manage
Slide 27: Recent Milestones
Recent Milestones Multiple Product Launches & Operational Enhancements Fueling Continued Market Penetration and Profitable Growth 2024 2025 YTD 2026 New exclusive U.S. distribution agreement ✓ Generated new clinical evidence among VA patients using Flexitouch ✓ Expanded Nimbl® System for lower extre
Slide 28: Durable Revenue & Profit Growth with Increasing Operating Cash Flow
Durable Revenue & Profit Growth with Increasing Operating Cash Flow ~16%* $329.5 $360 - $366 RE VE NU E CA GR $293.0 $274.4 $246.8 $208.1 $189.5 $187.1 $143.8 $109.3 $84.5 $49 - $29.7 $37.1 $44.8 $7.0 $9.8 $17.3 $25.3 $16.0 $17.7 $18.3 $51 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Guida
Slide 29: Strategic Priorities In-Place to Drive Sustainable & Profitable Growth
Strategic Priorities In-Place to Drive Sustainable & Profitable Growth Improve Patient Experience Increase Access Expand Treatment Enhance Lifetime to Care Options Patient Value ▪ Remove existing barriers: ▪ Nimbl, next-gen basic PCD, ▪ Serve patients over a longer ▪ Clinician and patient fully laun
Slide 30: Investment Highlights
Investment Highlights Leveraging Technology & Market Leadership to Deliver Profitable Growth ~$10B TAM* Strong Pipeline & Tech Strategy With significant greenfield Driving innovation, customer service, and operating leverage Broad Payer Support Extensive Distribution Reach With increasingly supporti
Slide 31: Appendix
Appendix TACTILE MEDICAL | 31
Slide 32: Financial Results: Q2 2026 & 2025, FY'25 & FY'24
Financial Results: Q2 2026 & 2025, FY’25 & FY’24 Three months ended June 30, Year Ended December 31, 3 MONTHS ENDED $ Millions 2026 2025 2025 2024 JUNE 30, 2026 $278.4 $259.4 Lymphedema products $73.6 $66.0 FINA NCI AL SUMMARY: Airway clearance products $12.1 $12.9 $51.1 $33.6 Total revenues $85.7 $
Slide 33: Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA
Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA Years ended December 31 ($ Millions) 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 $ $ $ Net income (loss) $ 19.1 $ 17.0 $ 28.5 (17.9) (11.8) (0.6) $ 11.0 $ 6.6 $ 5.9 $ 2.9 Interest (income) expense, net (2.1) (1.3) 2.3 2.7 0.5
Slide 34: Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA
Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA Increase Three Months Ended June 30, (Decrease) (Dollars in millions) 2026 2025 $ % Net income $ 7.8 $ 3.2 $ 4.6 142% Interest (income) expense, net (0.5) (0.4) (0.1) 23% Income tax expense (benefit) (0.4) 1.3 (1.7) (132%) Depreciation an
Slide 35: Reconciliation of FY 2026 GAAP Net Income to Adjusted EBITDA Guidance
Reconciliation of FY 2026 GAAP Net Income to Adjusted EBITDA Guidance Year ended December 31, 2026 (Dollars in millions) Low High Net income $ 23.2 $ 24.7 Interest (income) expense, net (2.4) (2.4) Income tax expense 9.4 10.0 Depreciation and amortization 7.5 7.5 Stock-based compensation 8.6 8.6 Acq
Slide 36: Select Comparisons from the Balance Sheet as of 6/30/2026 and 12/31/2025
Select Comparisons from the Balance Sheet as of 6/30/2026 and 12/31/2025 Increase (Decrease) (Dollars in millions) 6/30/2026 12/31/2025 $ % Cash $ 69.9 $ 83.4 $ (13.6) (16)% Accounts receivable 43.1 43.9 (0.7) (2)% Accounts receivable, non-current 0.0 0.0 0.0 0% Total accounts receivable 43.1 43.9 (